Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCORE FL-1: epcoritamab + R2 versus R2 in relapsed or refractory follicular lymphoma
CTR20230864Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of epcoritamab, rituximab, lenalidomide in follicular lymphoma (FL), sponsored by AbbVie Inc.. Started Jan 2024; status: active.
02
Drugs
epcoritamabrituximablenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20230864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230864.